



Vivimed

Date: 17.06.2022

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai 400 001
Scrip Code: **532660**

National Stock Exchange of India Limited
Exchange Plaza, Sandra Kurla Complex,
Bandra (E), Mumbai - 400 051
Symbol: **VIVIMEDLAB**

Dear Sir/ Madam,

Sub: Disclosure of Related Party Transactions for the Half Year Ended 31.03.2022

Ref. Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 ("Listing Regulations")

In compliance with the above referred Listing Regulations, please find enclosed herewith Related Party Transactions on a consolidated basis for the half year ended 31.03.2022.

Note that the financial results have been approved by the Board of Directors on 03.06.2022

Please take the same on record.

Thank you,
For Vivimed Labs Limited

K. Yugandhar
Company Secretary
ICSI Membership No: ACS-19315



Encl: As above

Vivimed Labs Limited.

CIN: L02411KA1988PLC009465

Registered Office: #78/A, Kolhar Industrial Area,
Bidar, Karnataka - 585 403, India.

T +91 (0) 8482-232045, F +91 (0) 8482-232436

Email: contact@vivimedlabs.com | www.vivimedlabs.com

Corporate Office:

North End, Road No. 2
Banjara Hills, Hyderabad,
Telangana - 500 034, India.

GSTIN: 36AAACV6060A1ZQ

T +91(0) 40-6608-6608, F +91(0) 40-6608-6699

Vivimed Labs Limited

Related Party Disclosures for the half year ended March 31, 2022

1	Key Management Personnel	Name	Nature of relationship/ Designation
		Mr. Santosh Varalwar	Managing Director
Dr. Manohar Rao Varalwar	Whole Time Director		
Mr. Subhash Varalwar	Non-Executive non – Independent Director		
Mr. Sandeep Varalwar	Whole Time Director		
Dr. Jamalapuram Harigopal	Independent Director		
Ms. Aparna Bidarkar	Independent Director - Appointed w.e.f. 14.02.2022		
Mrs.Umanath Varahabhotla	Independent Director- Resigned w.e.f. 10.01.2022		
Mr.Ramesh Krishnamurthy	Chief Executive Officer - Cum - Chief Financial Officer - Resigned w.e.f. 15.10.2022		
Mr. Yugandhar Kopparthi	Company Secretary & Compliance Officer		

Consolidated disclosure of related party transactions for the half year ended 31st March, 2022

Sl.No	Nature of Transaction	(Rs. In Millions)
1	Payment to Key Managerial personnel and Directors (This amount does not include the sitting fees paid to Non-Executive Directors)	16.35

Related Party Transactions for the half year ended 31st March, 2022

SI No	Party Name	Nature of Transaction	During Oct- Mar 2022
			Debit /(Credit) (Rs. In Millions)
1	Finoso Pharma Private Limited (100% Wholly owned Subsidiary)	Purchase of goods and services	8.25
2	BBR Projects Private Limited (Associate)	Product development advance	(19.74)
3	BBR Greenfields Private Limited (Associate)	Loans and Advance given	15.81

Yugandhar

